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ABSTRACT
Human papilloma virus type 5 (HPV-5) has been associated closely with psoriatic skin in Polish patients,
while ﬁndings from other countries have indicated a more limited prevalence. The results of the present
study, in which a type-speciﬁc nested PCR was used, indicated that scales of plaque-type psoriatic skin
from 54 Italian patients had a high prevalence (74.1%) of HPV-5 DNA in lesional areas, and a reduced
prevalence (33.3%) in non-lesional skin (33.3%), compared to 0% of 20 healthy subjects and 3.6% in the
lesional areas of 28 patients with various other dermatological diseases. Individuals negative for HPV-5
DNA had a less severe disease. No correlation was found between the presence of HPV DNA and a
patient’s age or sex. The data demonstrated a statistically signiﬁcant association between psoriasis and
HPV-5, although results in other geographical areas suggest variable virus spread or ethnic variation in
virus colonisation.
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INTRODUCTION
Previous reports have highlighted skin colonisa-
tion by human papilloma virus type-5 (HPV-5) in
plaque-type psoriatic patients [1]. HPV-5 has
been associated with epidermodysplasia verruc-
iformis and skin cancers in such patients [2,3],
and also with some bullous diseases, auto-
immune connective skin disorders and skin
cancers in psoriatic individuals treated with
ultraviolet light [4], all of which conditions are
linked to keratinocyte proliferation and ⁄ or exten-
sive re-epithelisation [5]. It should be noted that
other inﬂammatory diseases, such as atopic
dermatitis, and autoimmune diseases without
skin involvement, do not show a similar associ-
ation [2–5]. In addition, it has been reported that
anti-HPV-5 antibodies may arise in normal sub-
jects during epidermal repair processes following
burns [6], suggesting that this condition, like the
psoriatic lesions, is dependent on extensive
keratinocyte proliferation. It is interesting that
the antibody presence is transient, insofar as it
becomes detectable after 2–3 weeks and tends to
disappear after 6–20 months, suggesting that
virus replication and the humoral immune
response are also associated with vigorous ker-
atinocyte proliferation [5].
Psoriatic skin colonisation by HPV seems to be
restricted mainly to HPV-5 or, less frequently, to
HPV-36, whereas other genotypes, such as HPV-
1, are distributed equally in different skin disor-
ders, suggesting a possible involvement of
speciﬁc receptors for some HPV genotypes
exposed on the skin cells. A skin tropism for
several HPV types has been described [1,7],
and a locus for an abnormal predisposition to
infection with HPV-5 (characteristic of epider-
modysplasia verruciformis) maps to chromo-
some 17 qter in a region that contains one of
the psoriasis loci and several other genes
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involved in cutaneous diseases [8]. However,
HPV-5 may also be found in the skin of normal
individuals [9,10], suggesting that its presence is
not sufﬁcient in itself to induce psoriatic lesions,
although the phenomena caused by the localised
skin immune response might induce inﬂamma-
tory mechanisms and exacerbate the psoriatic
lesions through the release of proinﬂammatory
cytokines [11,12]. Alternatively, evidence that
hair follicles may represent a reservoir of
HPV-5 in normal subjects indicates that this
virus could be a ubiquitous virus that replicates
in hyper-reactive keratinocytes [10].
Following the ﬁrst report of an association
between HPV-5 and psoriasis in Polish patients,
only limited data have been reported from differ-
ent countries [4,13]. Such information might be
useful in establishing whether ethnic origin inﬂu-
ences the disease association, or whether geo-
graphical variations in virus spread play a role in
the extension and evolution of the disease. The
present study provided data on the prevalence of
HPV-5 DNA in Italian plaque-type psoriatic
patients, in comparison with normal individuals
or patients with other dermatological diseases.
Further data concerning the presence of HPV-5
DNA in lesional and ⁄ or non-lesional skin are
required in order to evaluate whether the severity
of disease is inﬂuenced by the virus load in
different patients.
MATERIALS AND METHODS
Patients and controls
In total, 54 consecutive Italian plaque-type psoriatic patients
were enrolled in the study of whom 21 (39%) were familial
and 33 (61%) were sporadic cases. The mean age was
41.9 ± 13.5 years, and the male ⁄ female ratio was 32:22. The
psoriasis area and severity index (PASI) score calculated [14]
for each patient varied between 5 and 70. Informed consent
was obtained from all patients. Also included in the study
were 20 healthy controls (mean age 40.2 ± 14.8 years; male ⁄
female ratio 12:8; non-lesional areas) and 28 patients (mean age
42.1 ± 16.4 years; male ⁄ female ratio 15:13) with other skin
diseases (11 atopic dermatitis, two prurigo, one mycosis
fungoides, one pytiriasis sicca, one scleroderma, one skin
ulcer of the leg, one hyperkeratosis, two lichen planus, one
chronic plantar eczema, one verruca vulgaris, one plantar
dermatitis, and ﬁve parapsoriasis with lesional areas). Diag-
noses were made following standard guidelines by the
dermatologists of the S. Gallicano Institute, Rome, on the basis
of patient history, clinical inspection and laboratory tests. Skin
areas from which scales were obtained were similar in the
three groups (neck, arm, forearm, leg, thigh, buttock, trunk,
hand, wrist and elbow).
DNA preparation and detection of HPV-5 DNA by nested
PCR
Brieﬂy, DNA was extracted from skin scales with the EXTRA-
cell reagent (EXT DO2; Amplimedical, Turin, Italy) according
to the manufacturer’s instructions. DNA quality was con-
trolled by ampliﬁcation of a DNA fragment of the b-globin
gene (DECK, DK100; Amplimedical).
Standard precautions and conditions for PCR analysis and
nested PCR procedures were used [15]. A type-speciﬁc nested
PCR was performed with a commercially available kit (HPV 5,
E6, BAN 855-02, BAN 855-05; Amplimedical) containing two
sets of primers designed to detect the HPV-5 E6 gene. The
sensitivity of the kit, as deﬁned by the manufacturer, is ten
virus genomes ⁄ reaction. The ﬁrst-round PCR, with primers
5¢-GGAAGCCTGYGAATTCGACTAC-3¢ (position 360–381 of
the HPV genome) and 5¢-CTTCCAGGCGTTCCTCACCT-3¢
(position 620–639 of HPV) generates a 280-bp product,
while the second round with internal primers 5¢-TGTG-
TTTGCGTGYTGTCGC-3¢ (position 414–432) and 5¢-CCTCT-
GCCACAGCAATCTAACTTT-3¢ (position 582–605) generates
a 192-bp product. All assays were performed in parallel with
positive and negative controls. As a positive control, 1 ng of
recombinant plasmid DNA containing a 280-bp fragment from
the HPV-5 E6 gene (see below) was always included, while the
negative control was the complete reaction mixture without
added template DNA.
Plasmid construction and test sensitivity
The positive control used in the nested PCRwas constructed by
cloning the initial 280-bp PCR product into pCRII-TOPO
plasmid (Invitrogen, Paisley, UK) according to the manufac-
turer’s instructions. Brieﬂy, resulting white colonies were
screened by PCR with M13 reverse and forward primers to
verify insertion of the fragment. One of the positive colonieswas
grown in 50 mL of L-broth (Kzackeler Scientiﬁc, Albany, NY,
USA) containing ampicillin (100 mg ⁄L), and the plasmid DNA
was extracted and puriﬁed with a QIAGEN plasmid DNA kit
(Qiagen, Milan, Italy) used according to the manufacturer’s
instructions. The presence of the HPV-5 E6 DNA fragment was
checkedby sequencing (MWGAGBiotechAnzinger, Ebersberg,
Germany). The recombinant plasmid DNA was used as a
positive control in all the subsequent reactions.
Sequencing analysis
The 192-bp PCR products obtained with the patient samples
were puriﬁed after electrophoresis in agarose 1% w ⁄v gels
with a QIAEX II Agarose Gel Extraction Kit (Qiagen), used
according to the manufacturer’s instructions, and were then
sequenced (MWG AG Biotech Anzinger). Primers used for the
nested PCR were also used as primers for sequencing.
Computer analysis of sequence information was performed
with the Nucleotide BLAST query program (http://
www.ncbi.mlm.nih.gov).
Statistical analysis
Chi-square tests, contingency tables or non-parametric Krusk-
all–Wallis tests (necessary to evaluate score differences) were
used as appropriate, with p values < 0.05 considered statisti-
cally signiﬁcant.
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RESULTS
In order to ﬁrst establish the sensitivity range of
the procedure when used in this project, ten-fold
serial dilutions of HPV-5 E6 plasmid DNA,
starting with 1 ng of puriﬁed DNA, were ampli-
ﬁed in 50-lL PCR mixtures. Ampliﬁcation still
occurred with a 10)6 dilution, corresponding to c.
20 molecules of recombinant HPV-5 E6 plasmid
DNA. Non-speciﬁc ampliﬁcation of other HPV
types (HPV-6, -11, -16, -18, -31 and -33) was not
observed with the HPV-5-speciﬁc primers.
When the 54 plaque-type psoriatic patients
were analysed for the presence of HPV-5 DNA
in two different skin samples (lesional and non-
lesional areas), 40 (74.1%) patients were positive
in lesional areas, of whom 18 (33.3%) were also
positive in non-lesional areas (p < 0.001). All
assays were positive following ampliﬁcation for
the b-globin gene, thereby indicating that DNA
extraction was successful and that no PCR inhib-
itors were present.
Fig. 1 shows representative results obtained
following agarose gel electrophoresis of nested
PCR products from HPV-5-positive or -negative
samples. All positive samples were conﬁrmed
subsequently as HPV-5 by direct nucleotide
sequencing, with a minimum 95% identity.
Skin samples from 20 healthy controls, of a
similar sex and age distribution to the psoriatic
group, were negative (p < 0.001 vs. both lesional
and non-lesional areas). One (3.6%) HPV-5-pos-
itive patient (with chronic eczema) was found
among the 28 patients affected by various other
skin disorders (p < 0.001 vs. lesional or non-
lesional areas of psoriatic patients; no signiﬁcant
difference vs. healthy controls).
There was no statistically signiﬁcant correla-
tion between HPV-5 detection and age, sex or
skin areas (Table 1), or between skin areas
exposed or unexposed to ultraviolet light. When
the PASI score was analysed, a signiﬁcant dif-
ference was found between HPV-5 DNA-negat-
ive individuals and patients positive for lesions
or for both lesional and non-lesional areas
(Table 2; p 0.012). There was no difference
between familial and sporadic psoriatic patients
with respect to lesional or non-lesional HPV-5
DNA prevalence.
DISCUSSION
Previous studies have shown that HPV-5 DNA is
found frequently in individuals affected with
epidermodysplasia verruciformis, skin carcino-
mas, bullous diseases, some autoimmune diseases
and, particularly, psoriasis [1–6,16]. Less fre-
quently, other HPV types have been reported,
sometimes also associated with psoriatic patients.
Interestingly, anti-HPV-1 antibodies are not detec-
ted differentially in the same pathologies, sug-
gesting that special mechanisms support skin
colonisation by HPV-5 [6]. However, recent data
suggest that hair follicles constitute a reservoir of
HPV, and that HPV-5 is a ubiquitous virus that
replicates at a high rate in hyper-reactive psoriatic
keratinocytes [5,6,9,10].
Fig. 1. Examples of HPV-5 nested PCR products following
electrophoresis in ethidium bromide-stained agarose 2%
w ⁄ v gels. Lanes: M, molecular size markers; 1, positive
control obtained with HPV-5 E6 recombinant plasmid
DNA; 2, negative control (reaction mix without added
template DNA); 3 and 4, HPV-5 DNA-negative skin; 5 and
6, skin scales of psoriasic lesions.
Table 1. Skin site distribution of human papilloma virus
DNA in psoriatic patients
Body site
Lesional area Non-lesional area
No. Positive % No. Positive %
Upper limbs 42 30 71 46 15 33
Lower limbs 8 6 75 3 1 33
Neck and trunk 4 4 100 5 2 40
Contingency table for lesional area: p > 0.05.
Contingency table for non-lesional area: p > 0.05.
Table 2. Association between PASI score and human
papilloma virus type 5 (HPV-5) DNA positivity in lesional
and non-lesional areas
HPV-5 DNA No. of patients
PASI score
Median Range
Negative 14 13.0 8–23
Positive (lesion) 22 16.0 5–34
Double positive 18 19.0 9–70
p 0.012.
PASI, psoriasis area and severity index.
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The results obtained in the present study of
Italian psoriatic patients were very similar to
those reported for psoriatic individuals in Poland
[1], suggesting that the frequency of virus coloni-
sation is very high in these two countries. In
contrast, German and Austrian patients [4], as
well as psoriatic patients in France [13], showed
lower frequencies of 38% and 46%, respectively,
possibly suggesting that different geographical
areas may have different rates of virus spread.
The present study was directed towards psori-
atic skin, and the signiﬁcantly higher colonisation
frequencies observed in the lesional areas sug-
gested that the virus is more prevalent where
inﬂammatory mechanisms are activated and ker-
atinocytes are proliferating. This observation is in
agreement with the ﬁnding in normal individuals
that HPV-5 DNA and antibody detection rates
increase concomitantly with skin repair phenom-
ena [6]. Previous studies of psoriasis have also
shown that even uninvolved skin undergoes
various biochemical modiﬁcations, such as acti-
vation of inﬂammatory processes [11], and this
was perhaps reﬂected in the degree of HPV-5
DNA positivity recorded in the present study for
non-lesional skin, which was midway between
the ﬁgures for normal and lesional psoriatic skin.
This may also indicate that the virus DNA is
present in low amounts and becomes detectable
only after cell proliferation has begun [7], possibly
depending on proinﬂammatory cytokine release
[12], as indicated also by the ﬁnding of increased
positivity in burns [6]. The present study found a
lower rate of positivity in the skin of healthy
subjects as compared with other published data
[10], but this difference may be a result of
different sampling methods, selecting hair folli-
cles instead of skin scales. Different methods used
to study HPV types in the skin may also account
for differences in the prevalence observed, par-
ticularly with respect to other genotypes [17–19].
To date, only HPV-5 and HPV-36 have been
associated with psoriasis [1].
Analysis of samples taken from different skin
areas did not show signiﬁcant differences in HPV-
5 DNA positivity, suggesting that the presence of
HPV-5 DNA depended more on keratinocyte
proliferation than on body localisation. Since
HPV replication is known to be activated
when keratinocyte replication is active, it can be
speculated that the psoriatic keratinocyte is a
particularly suitable host for HPV-5 viruses [7],
which perhaps utilise a receptor molecule that is
exposed particularly on psoriatic keratinocytes.
Other skin diseases, such as parapsoriasis or
eczema, seem not to be associated with HPV-5,
even if the inﬂammatory mechanisms may be
activated similarly. A possible involvement of
HPV-5-induced early (E6 ⁄E7) and late (L1) pro-
teins in the immunopathogenesis of psoriasis has
been suggested [20]. Alternatively, as suggested
by the frequent presence of this virus in the hair
follicles of healthy individuals, HPV-5 detection
may be favoured by its enhanced replication in
activated keratinocytes, particularly in psoriatic
processes, where several cytokines capable of
inducing keratinocyte proliferation are released
in inﬂamed tissues [11], which would be in
keeping with other models for HPV replication
[21–23].
In the present study, patient age did not
correlate with HPV-5 positivity, indicating that
skin colonisation may happen very early, as
suggested by data [13] concerning a psoriatic
baby with early HPV-5 DNA positivity. A study
of psoriatic and healthy newborns and children in
the early years of life would help to clarify this
point. No data are available at the present time
regarding HPV-5 transmission from mother to
child. The fact that sporadic and familial psoriatic
patients do not show differences in HPV DNA
prevalence accords with the hypothesis that all
proliferating infected keratinocytes may produce
virus progeny, independently of whether or not
the psoriasis is familial. The PASI score was
evaluated in psoriatic subjects divided into three
groups according to the presence of HPV-5 DNA:
(1) negative; (2) positive only in lesional samples;
and (3) positive in both lesional and non-lesional
skin samples. There was a signiﬁcant difference
between the groups, suggesting that disease
severity and the presence of HPV-5 were associ-
ated.
In conclusion, the data from this study con-
ﬁrmed that plaque-type psoriatic skin of Italian
patients was a reservoir of HPV-5. The prevalence
was very high in the lesional areas and less so in
non-lesional skin, while HPV-5-negative subjects
seemed to have a less severe disease. Ultraviolet
light has been reported to be a cofactor in
HPV-associated skin tumourigenesis [24], but no
signiﬁcant variations in HPV-5 positivity were
observed between skin areas exposed or unexpo-
sed to ultraviolet light. Although detection of
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HPV-5 may be a simple reﬂection of keratinocyte
proliferation, the possibility that HPV-5 acts as a
trigger for the clinical manifestation of the disease
by inducing a local immune response, including
proinﬂammatory mediators, leading to subse-
quent keratinocyte proliferation (similarly to
other infectious agents), is an interesting possibil-
ity that deserves further study [20].
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